The global pet longevity therapeutics market size was estimated at USD 577.6 million in 2025 and is projected to reach USD 1,145.9 million by 2033, growing at a CAGR of 9.13% from 2026 to 2033. The market is experiencing significant growth as pet owners increasingly view their companion animals as integral members of the family, driving greater investment in advanced healthcare solutions designed to extend both lifespan and quality of life. The growing trend of pet humanization has encouraged consumers to adopt the same longevity-focused health approaches for their pets that they pursue for themselves. This shift has increased demand for innovative longevity therapeutics, nutritional interventions, preventive treatments, and wellness products aimed at supporting healthy aging. In addition, rising disposable incomes and a willingness to spend on premium pet care solutions are contributing to the expansion of the market across developed and emerging economies.

Another major factor accelerating market growth is the rapid advancement of companion animal geroscience and the expanding body of biological evidence supporting the modulation of aging pathways in non-human species. Researchers and industry participants are increasingly focused on understanding the biological mechanisms associated with aging, enabling the development of targeted therapeutics designed to address age-related decline in pets. The rising prevalence of chronic diseases associated with aging, including cognitive dysfunction and other degenerative conditions, has further strengthened demand for longevity-focused solutions. As awareness regarding preventive healthcare continues to increase among pet owners, investments in healthspan-enhancing therapies, supplements, and specialized treatments are expected to create substantial opportunities for industry participants throughout the forecast period.

Download a free sample copy of the Pet Longevity Therapeutics market report to understand detailed coverage and inclusions in the final report

Key Market Trends & Insights

·         North America dominated the global pet longevity therapeutics market with the largest revenue share of 39.3% in 2025. The region's leadership is supported by strong pet healthcare spending, advanced veterinary infrastructure, high pet ownership rates, and growing awareness regarding preventive wellness solutions. Continuous innovation and increasing adoption of premium pet healthcare products are further contributing to market expansion across the region.

·         The pet longevity therapeutics industry in the U.S. accounted for the largest market revenue share in North America in 2025. The country's established veterinary ecosystem, strong consumer spending on companion animal health, and increasing interest in longevity science have positioned it as a key contributor to regional growth. Market participants continue to invest in research, development, and commercialization of innovative longevity-focused products aimed at improving pet health outcomes.

·         By product, the supplements segment accounted for the largest market revenue share in 2025 and is projected to grow at the fastest CAGR during the forecast period. The increasing preference for nutritional interventions, preventive healthcare strategies, and daily wellness support has strengthened demand for supplements designed to promote healthy aging and overall vitality in companion animals.

·         By pet, the canine segment accounted for the largest market revenue share in 2025. Dogs represent a significant share of companion animal ownership globally, and growing awareness regarding age-related health challenges among canine populations has increased demand for longevity-supporting therapeutics and wellness solutions.

·         By indication, the cognitive aging and neuroprotection segment accounted for the largest market revenue share in 2025. As pets live longer lives, concerns related to cognitive decline and neurological health are becoming increasingly important among pet owners and veterinary professionals. This trend is encouraging the adoption of products focused on maintaining cognitive function and supporting long-term brain health.

Looking for more specific insights? Customize this report to suite your business needs

Key Companies & Market Share Insights

The global pet longevity therapeutics industry is characterized by a diverse competitive landscape spanning multinational nutrition conglomerates, specialized veterinary supplement developers, and emerging longevity-focused entrants. Companies across the ecosystem are actively investing in innovation, product development, and scientific research to strengthen their market positions and address the growing demand for solutions that enhance pet lifespan and healthspan.

Key Pet Longevity Therapeutics Companies:

·        Leap Years

·        RENUE BY SCIENCE, Inc.

·        PurePet

·        Thorne Vet.

·        Nestlé S.A

·        Quincy Bioscience

·        Zesty Paws

·        Antinol

·        Nutramax Laboratories

·        La Petite Labs

·        Arterra

·        Hill’s Pet Nutrition

·        PETMADE

·        Petlio

·        Kormotech

·        Animal Essentials

·        Vitality Science

·        Longevity for Animals

·        Royal Canin

Explore Grand View Horizon to see global and regional level statistics related to the Pet Longevity Therapeutics Market

Grand View Research offers

·         Focused market intelligence reports on specific geographies or high-growth segments.

·         Extended forecast timelines for long-term planning.

·         Competitor Benchmarking and Supply Chain Analysis

·         Inclusion of regulatory and policy assessments.

·         Inclusion of custom data models, KPIs, or applications unique to your business

·         Specific high-impact Data Decks and Tables to support effective decision making

·         And much more…

Looking for a report customized to your requirements? Explore our Custom Research Offering